Menu

Image of the Day: Hungry Hookworms

Researchers discover anti-malarials called quinolones can halt the development of the parasites, offering a potential therapeutic avenue.

Mar 26, 2018
The Scientist Staff, The Scientist Staff

Adult hookworm (Nippostrongylus brasiliensis) with digested blood cells labeled with fluorescent marker PKH26T. BOUCHERY ET AL.

Researchers reported in PLOS Pathogens last week (March 22) that they have identified a pathway in hookworms (Nippostrongylus brasiliensis) involved in blood digestion that can be blocked by drugs in the quinolone family. Treating mice infected with hookworms reduced the parasites’ development and their ability to reproduce.

Tiffany Bouchery, a parasitologist at Malaghan Institute of Medical Research in New Zealand, and colleagues targeted an enzyme, aspartic protease-1 (APR-1), involved in the hookworms’ ability to break down a blood molecule called heme into digestible components. They tested the effects of quinolones, which break up similar compounds in malaria parasites, on the hookworms. The drugs disrupted the production of APR-1, and mice treated with them had lower levels of infection than controls.

T. Bouchery et al., “A novel blood-feeding detoxification pathway in Nippostrongylus brasiliensis L3 reveals a potential checkpoint for arresting hookworm development,” PLOS Pathogens, doi:10.1371/journal.ppat.1006931, 2018.

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.